Literature DB >> 24129683

Hypercoagulability, parkinsonism, and Gaucher disease.

Hanna Rosenbaum1, Judith Aharon-Peretz, Benjamin Brenner.   

Abstract

Gaucher disease (GD) is a lysosomal disorder caused by inherited deficiency of glucocerebrosidase (GCase), resulting in the accumulation of glucocerebroside in macrophages, termed "Gaucher cells," leading to multiorgan involvement, with hepatosplenomegaly, cytopenias, pulmonary hypertension, and skeletal complications. Various mutations, encoding the GCase gene, cause acute or chronic neuronopathic forms of the disease. The hallmark of GD is the macrophages infiltrating organs, bone marrow, and nervous system compromising their function by inflammation, infarcts, fibrosis, and neuronal damage. Coagulation abnormalities are frequent among GD patients due to reduced production and chronic consumption of coagulation factors. Splenic and bone infarcts often occur in GD patients, but hypercoagulability is not frequent. Detection of thrombophilic risk factors in GD patients may predict a more severe course of the disease. Clinical and genetic studies revealed an association between reduced GCase activity in carriers of GD mutations and GD patients and occurrence of Parkinson disease (PD) and showed that GCase gene mutations are risk factors for PD development. The mechanisms underlying the association of PD and GD are not yet elucidated and should be further explored, particularly the potential involvement of inflammation and coagulation in the neurovascular unit. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129683     DOI: 10.1055/s-0033-1357485

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  4 in total

1.  Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.

Authors:  Etheresia Pretorius; Martin J Page; Sthembile Mbotwe; Douglas B Kell
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

2.  High rates of blood transfusion associated with Parkinson's disease.

Authors:  Shane Shahrestani; Julian Gendreau; Ali R Tafreshi; Nolan J Brown; Khashayar Dashtipour
Journal:  Neurol Sci       Date:  2022-05-02       Impact factor: 3.830

3.  Pharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional chinese medicine.

Authors:  Hung-Jin Huang; Cheng-Chun Lee; Calvin Yu-Chian Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-19       Impact factor: 2.629

4.  Parkinson's Disease: A Systemic Inflammatory Disease Accompanied by Bacterial Inflammagens.

Authors:  Büin Adams; J Massimo Nunes; Martin J Page; Timothy Roberts; Jonathan Carr; Theo A Nell; Douglas B Kell; Etheresia Pretorius
Journal:  Front Aging Neurosci       Date:  2019-08-27       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.